摘要
以免疫检查点抑制剂为代表的免疫疗法开创了肿瘤治疗的新途径,已在泛癌种患者中展现了持久的临床获益,但仅有一小部分患者治疗有效,且特异性的免疫相关不良事件和肿瘤超进展限制了其应用。因此开发预测性生物标志物,以筛选获益人群、最大程度降低毒性风险是目前的研究热点。本文综述了免疫检查点抑制剂抗肿瘤免疫治疗的相关预测标志物研究进展,并展望了其在精准免疫治疗方面的未来方向。
Immune checkpoint inhibitors(ICIs)-based immunotherapy has created a new era of anti-cancer therapy and has shown durable clinical benefits in pan-cancer patients.Unfortunately,only a fraction of patients can response to ICIs.Moreover,specific immune-related adverse events and hyperprogressive diseases limit its application.Thus,it is imperative to identify valid biomarkers in optimizing patient selection for maximizing the clinical benefits and minimizing the risk of toxicity.The current progress of predictive biomarkers for ICIs are comprehensively summarized and their future directions in achieving precision immuno-oncology are discussed in this review.
作者
冀寿健
徐建明
JI Shoujian;XU Jianming(Department of Gastroenterology,the 960th Hospital of the PLA,Jinan 250031,Shandong Province,China;Department of Gastrointestinal Oncology,the Fifth Medical Center of PLA General Hospital,Beijing 100853,China)
出处
《解放军医学院学报》
2025年第3期302-308,共7页
Academic Journal of Chinese PLA Medical School
基金
国家自然科学基金面上项目(82072613)。
